Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Diseases of the Liver and Gallbladder01:26

Diseases of the Liver and Gallbladder

Liver and gallbladder diseases are a significant health concern, with prominent conditions including cirrhosis, hepatitis, non-alcoholic fatty liver disease (NAFLD), and gallstones. Jaundice is a common manifestation of liver and biliary disease.
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not related to...
Hepatitis01:25

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
Viral Hepatitis I: Introduction01:28

Viral Hepatitis I: Introduction

Viral hepatitis is an inflammatory condition of the liver caused by infection with hepatotropic viruses, most commonly hepatitis A, B, C, D, and E. Despite variations in structure and transmission, all viruses mentioned infect hepatocytes and provoke immune responses that can hinder liver function. Additionally, some non-hepatotropic viruses can also lead to hepatic inflammation.Hepatitis A VirusHepatitis A virus (HAV) is transmitted through the fecal–oral route, typically by ingestion of food...
Cirrhosis I: Introduction01:23

Cirrhosis I: Introduction

Cirrhosis is a chronic, irreversible liver disease characterized by the widespread replacement of healthy liver tissue with fibrotic scar tissue and the formation of regenerative nodules.Etiology of cirrhosisCirrhosis results from sustained liver injury that triggers progressive fibrosis and structural remodeling. The underlying causes are diverse, encompassing common and less frequent clinical conditions. Regardless of the origin, all causes lead to chronic inflammation, hepatocyte loss, and...
Cirrhosis II: Pathophysiology01:24

Cirrhosis II: Pathophysiology

Cirrhosis is a progressive chronic liver injury caused by prolonged inflammation, excessive fibrotic remodeling, and impaired regeneration. Over time, repeated hepatic insults disrupt the liver’s architecture and function, leading to reduced blood flow, impaired bile drainage, and diminished metabolic capacity.Pathophysiology of cirrhosisCirrhosis arises from three main responses to chronic liver damage: inflammation, immune activation, and hepatocyte death. These processes lead to structural...
Chronic Pancreatitis II: Pathophysiology01:21

Chronic Pancreatitis II: Pathophysiology

Chronic pancreatitis is a progressive and irreversible inflammation of the pancreas, most often caused by long-term alcohol abuse, but it can also be related to ductal obstruction, smoking, or genetic factors.Chronic pancreatitis occurs when the pancreas is repeatedly exposed to harmful agents like alcohol, smoking, ductal obstruction, or genetic predisposition. These factors lead to the release of toxic metabolites and inflammatory cytokines, sustaining chronic inflammation in the pancreatic...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Same disease, different impact.

Inflammatory bowel diseases·2001
Same author

The impact of interferon plus ribavirin on response to therapy in black patients with chronic hepatitis C. The International Hepatitis Interventional Therapy Group.

Gastroenterology·2000
Same author

The significance of hepatitis G virus in serum of patients with sporadic fulminant and subfulminant hepatitis of unknown etiology.

Blood·1999
Same author

Hepatitis C virus genotypes and viremia and hepatocellular carcinoma in the United States.

The American journal of gastroenterology·1999
Same author

Transgenic expression of tpr-met oncogene leads to development of mammary hyperplasia and tumors.

The Journal of clinical investigation·1996
Same author

Association of hepatitis C virus and hepatocellular carcinoma in the United States.

Princess Takamatsu symposia·1995
Same journal

How important is fiber in the Crohn's disease story?

Gastroenterology·2026
Same journal

Reply to "Critical Appraisal of the Integrin αV-YAP-CTGF Axis in Congestive Hepatopathy".

Gastroenterology·2026
Same journal

Critical Appraisal of the Integrin αV-YAP-CTGF Axis in Congestive Hepatopathy.

Gastroenterology·2026
Same journal

A High-Risk Impaction: To Scope or to Stent First?

Gastroenterology·2026
Same journal

Epithelial FOXP3 Orchestrates O-Glycosylated IL6 Secretion to Drive Pancreatic Fibrocarcinogenesis.

Gastroenterology·2026
Same journal

Reply.

Gastroenterology·2026
See all related articles

Related Experiment Video

Updated: Jun 30, 2026

Incorporation of a Survivable Liver Biopsy Procedure in Mice to Assess Non-alcoholic Steatohepatitis (NASH) Resolution
04:14

Incorporation of a Survivable Liver Biopsy Procedure in Mice to Assess Non-alcoholic Steatohepatitis (NASH) Resolution

Published on: April 16, 2019

Nonalcoholic steatohepatitis.

A E Reid1

  • 1Gastrointestinal Unit, Massachusetts General Hospital, Boston, Massachusetts 02114, USA. areid@partners.org

Gastroenterology
|August 28, 2001
PubMed
Summary
This summary is machine-generated.

Nonalcoholic steatohepatitis (NASH) is a liver condition often linked to obesity and diabetes. Current treatments are unproven, but weight loss is recommended, and liver transplantation is an option for severe cases.

More Related Videos

A Model of Experimental Steatosis In Vitro: Hepatocyte Cell Culture in Lipid Overload-Conditioned Medium
08:35

A Model of Experimental Steatosis In Vitro: Hepatocyte Cell Culture in Lipid Overload-Conditioned Medium

Published on: May 18, 2021

Mouse Model of Metabolic Dysfunction-Associated Steatotic Liver Disease with Fibrosis
06:26

Mouse Model of Metabolic Dysfunction-Associated Steatotic Liver Disease with Fibrosis

Published on: July 18, 2025

Related Experiment Videos

Last Updated: Jun 30, 2026

Incorporation of a Survivable Liver Biopsy Procedure in Mice to Assess Non-alcoholic Steatohepatitis (NASH) Resolution
04:14

Incorporation of a Survivable Liver Biopsy Procedure in Mice to Assess Non-alcoholic Steatohepatitis (NASH) Resolution

Published on: April 16, 2019

A Model of Experimental Steatosis In Vitro: Hepatocyte Cell Culture in Lipid Overload-Conditioned Medium
08:35

A Model of Experimental Steatosis In Vitro: Hepatocyte Cell Culture in Lipid Overload-Conditioned Medium

Published on: May 18, 2021

Mouse Model of Metabolic Dysfunction-Associated Steatotic Liver Disease with Fibrosis
06:26

Mouse Model of Metabolic Dysfunction-Associated Steatotic Liver Disease with Fibrosis

Published on: July 18, 2025

Area of Science:

  • Hepatology
  • Gastroenterology
  • Internal Medicine

Background:

  • Nonalcoholic steatohepatitis (NASH) is characterized by liver enlargement, elevated aminotransferases, and histological changes mimicking alcoholic hepatitis, occurring without alcohol abuse.
  • NASH predominantly affects obese women and is frequently associated with metabolic conditions like diabetes mellitus, hypercholesterolemia, and hypertriglyceridemia.
  • While often asymptomatic, NASH can present with hepatomegaly, and laboratory findings typically show elevated serum aminotransferase levels with normal liver function tests.

Purpose of the Study:

  • To describe the clinical characteristics, histology, pathogenesis, natural history, and treatment of Nonalcoholic Steatohepatitis (NASH).

Main Methods:

  • Review of existing literature on NASH, focusing on clinical presentation, diagnostic criteria, and pathological findings.
  • Discussion of potential pathogenetic mechanisms, including lipid peroxidation and oxidative stress.
  • Evaluation of current and potential therapeutic strategies, including lifestyle modifications and pharmacological interventions.

Main Results:

  • Histological examination reveals moderate to severe macrovesicular steatosis, lobular hepatitis with necrosis or ballooning degeneration, and potential fibrosis.
  • The pathogenesis is not fully understood but is strongly implicated by lipid peroxidation and oxidative stress.
  • NASH appears to be a stable condition in most patients, though its long-term natural history remains largely unknown.

Conclusions:

  • Treatment for NASH is currently unproven, with weight reduction being the primary recommendation for obese patients.
  • While some drugs have shown promise in small studies, definitive evidence from large clinical trials is pending.
  • Orthotopic liver transplantation remains the established treatment for end-stage liver disease resulting from NASH.